APOA1 and ovarian cancer: In addition, a combination of Apo-A1, TT, Connective tissue activating peptide III (CTAPIII) and CA125 achieved a sensitivity of up to 84% and a specificity of 98% in distinguishing women with early stage ovarian cancer from healthy individuals [40].